Satellite Symposia
The 2008 MPS Conference will be presenting some very interesting and innovative pharma sponsored satellite symposia. These symposia are open to Professional Delegates only and have limited attendance available. Don’t miss out! Please be sure to register early for the symposia you are interested in when completing your conference registration.
Friday, June 27 SOLD OUT
Pharma Symposium Breakfast – 7:00am to 8:15am
Sponsored by: 
Pharmaceutical
*this symposium will provide 1 AMA PRA Category 1 CME*
Supported by an unrestricted educational grant from Biomarin Pharmaceutical, Inc
Breakfast provided
Enzyme Replacement Therapy in Mucopolysaccharidosis VI:
Clinical Experience With Galsulfase
Session Learning Objectives
Purpose: To provide clinicians with an overview of the long-term clinical safety and efficacy of galsulfase in the treatment of MPS VI, and help clinicians develop skills to apply these data to clinical practice.
| 1. |
Explain the natural history of MPS VI and historical outcomes with traditional therapies. |
| 2. |
Discuss the safety and efficacy of galsulfase in the treatment of MPS VI, including long-term results from the Clinical Surveillance Program. |
| 3. |
Describe how to incorporate clinical data on galsulfase into clinical practice, as explemlified by practical case reports. |
Agenda:
| 7:10am – 7:15am |
Introduction and Program Review
Program Moderator – Gregory Pastores, MD
New York Medical Hospital
|
| 7:15am – 7:30am |
Clinical Safety Profile of Galsulfase:
What Do We Know After 7 Years?
Paul Harmatz, MD
Children’s Hospital and Research Center, Oakland
|
| 7:30am – 8:00am |
Treatment of MPS VI with Galsulfase in Siblings: Case Reports
James McGill, MD (7:30am – 7:45am)
Royal Children’s Hospital
&
Angela Scheuerle, MD (7:45am – 8:00am)
Tesserae Genetics
|
| 8:00am – 8:15am |
Questions, Answers and Panel Discussion |
Friday, June
27 SOLD OUT
Pharma Symposium Lunch – 12:30pm to 1:45pm
Sponsored by: 
Lunch provided
Listening to the MPS Community – Can we build a future together?
Session Learning Objectives:
| 1. |
Share lessons learned from different projects focused on patients and agree to build learnings into future projects |
| 2. |
Explain what the MPS I Registry is and how families and physicians can benefit from it; explain how the information is disseminated |
| 3. |
Identify expectations/areas for improvement through discussion and symposium feedback |
Agenda:
| 12:30pm – 12:35pm |
Opening
Chairman (TBC) |
| 12:35pm – 12:55pm |
MPS I Overview
International Board Representative (TBC) |
| 12:55pm – 1:15pm |
International Patient Satisfaction Survey
Walt Harris, Genzyme Corporation |
| 1:15pm – 1:35pm |
Patients Narrative
Christine Lavery, UK Patients Society |
| 1:35pm – 1:45pm |
Discussions – Building a future together |
Saturday, June 28 SOLD OUT
Pharma Symposium Lunch – 1:05pm to 2:20pm
Sponsored by: 
*This symposium will provide 1.25 AMA PRA Category 1 CME*
Lunch provided
Moving Forward: The Past, Present, and Future of
Managing the Patient with MPS 2 and 3
Session Learning Objectives:
| 1. |
Explore the impact of early identification, diagnosis and management in patients
with MPS 2 and 3 |
| 2. |
Identify neurocognitive deficits in patients with MPS 2 and 3 and current and future therapeutic approaches designed to combat these deficits |
| 3. |
Assimilate case studies of patients with MPS 2 and 3, including differentiating approaches for mild, moderate and severe patients |
Agenda:
| 1:05pm – 1:10pm |
Introductions Lorne Clarke, MD |
| 1:10pm – 1:20pm |
Assessment of Current Approaches to Identification and Management of MPS 2 and 3 using an Audience Response System, Lorne Clarke, MD |
| 1:20pm – 1:45pm |
MPS and the Central Nervous System: Therapies and Outcomes, Maria Escolar, MD |
| 1:45pm – 2:10pm |
Future Directions in MPS 2 and 3 Therapy, Joseph Muenzer, MD, PhD |
| 2:10pm – 2:20pm |
Post-Program Audience Response System Questions and Answers, Faculty & Audience, Lorne Clarke, MD |
